May 25
BSE+NSE Vol: 69.05 k
News and Views
Glaxosmithkline Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening momentum across multiple timeframes, raising concerns for investors amid a challenging market backdrop.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
May 11: Stock opens at Rs.2,435.95 amid broad market decline
May 13: Q4 FY26 results reveal margin compression despite strong ROE
May 14: Flat quarterly performance reported amid shifting financial trends
May 15: Week closes at Rs.2,439.75, down 1.81% for the week
Glaxosmithkline Pharmaceuticals Ltd has declared a dividend. Dividend Details: - Percentage announced: 570% - Amount per share: 12 per share - Ex-date: Nov-07-2024 Dividend Yield: 0% Total Returns by Period: In the 3 Months period, the price return was -5.94%, the dividend return was 2.20%, resulting in a total return of -3.74%. In the 6 Months period, the price return was -1.54%, the dividend return was 2.30%, leading to a total return of 0.76%. Over the 1 Year period, the price return was -15.05%, the dividend return was 2.05%, culminating in a total return of -13.0%. In the 2 Years period, the price return was 22.8%, the dividend return was 4.28%, resulting in a total return of 27.08%. For the 3 Years period, the price return was 90.57%, the dividend return was 10.19%, leading to a total return of 100.76%. In the 4 Years period, the price return was 63.56%, the dividend return was 12.80%, culmina...
Read full news articleGlaxoSmithKline Pharmaceuticals Ltd's latest financial results for the quarter ended March 2026 present a mixed operational picture. The company reported net sales of ₹995.30 crores, reflecting a sequential decline of 4.41% compared to the previous quarter, marking the second consecutive quarter of revenue contraction. Year-on-year, however, net sales showed a modest growth of 2.15%. In terms of profitability, the net profit for the same quarter was ₹277.86 crores, which also represented a sequential decline of 6.01% from the prior quarter. On a year-on-year basis, net profit exhibited a growth of 5.70%. The operating margin stood at 35.26%, slightly down from 35.66% in the previous quarter, indicating some pressure on profitability metrics despite maintaining a strong position relative to industry averages. The company has demonstrated exceptional return on equity at 55.83%, highlighting its efficiency i...
Read full news article
Glaxosmithkline Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. The company’s financial trend score has declined sharply from 7 to 0 over the past three months, signalling a pause in revenue momentum and margin expansion that investors had come to expect from this mid-cap pharmaceutical player.
Read full news article
GlaxoSmithKline Pharmaceuticals Ltd., the Indian subsidiary of global biopharma giant GSK Plc., reported a net profit of ₹277.86 crores for Q4 FY26, marking a decline of 6.01% quarter-on-quarter whilst posting a modest 5.70% year-on-year growth. The ₹41,704 crore mid-cap pharmaceutical company's shares traded at ₹2,406.85 on May 13, down 1.68% from the previous close, reflecting investor concerns over sequential margin compression despite the company maintaining an exceptional return on equity of 55.83%.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news article
Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.
Read full news articleAnnouncementGlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Change of name of Registrar and Transfer Agent'.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Submission of Disclosure on Related Party Transactions '.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Results publication '.
Corporate Actions
No Upcoming Board Meetings
Glaxosmithkline Pharmaceuticals Ltd has declared 570% dividend, ex-date: 29 May 26
No Splits history available
Glaxosmithkline Pharmaceuticals Ltd has announced 1:1 bonus issue, ex-date: 11 Sep 18
No Rights history available
